Cue Biopharma (CUE) Stock
Early stage biotech developing cancer immune treatments. Here's the price, business snapshot, and what's worth knowing about Cue Biopharma in June 2026.
Cue BioPharma (ticker: CUE) is a clinical-stage biotechnology company developing targeted immune activators designed to engage a patient’s own immune system against cancer. Its technology seeks to direct and amplify antigen-specific T cell responses, with lead candidates in oncology indications. As an early-stage biopharma with a market capitalisation around $63.4m, Cue is research- and development‑intensive and typically reports limited or no commercial revenue. Key points for investors include the binary nature of clinical trial readouts, dependence on successful regulatory interactions, and the potential need for additional financing which can dilute shareholders. The share price can be volatile and sensitive to scientific data, partnership news and funding updates. For many investors, Cue may be better suited to a small, speculative part of a diversified portfolio. This is educational information only and not personalised advice — clinical outcomes are uncertain and past behaviour is not a reliable guide to future performance.
Stock Performance Snapshot
Analyst Rating
Analysts advise selling CUE Biopharma's stock due to a significant drop in expected value.
Financial Health
CUE Biopharma is showing solid revenue and cash flow, indicating good operational performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CUE
Oncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial Readouts Matter
Clinical data are primary value drivers for Cue; positive or negative results can move the stock sharply, though outcomes are uncertain.
Binary Clinical Risk
As an early-stage biotech, Cue faces high binary risk around trial outcomes and regulatory decisions; potential reward comes with elevated volatility.
Partnerships & Funding
Licensing deals or successful financing can de‑risk development and extend runway, but funding needs may also dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
